Literature DB >> 913456

The treatment of advanced carcinoma of the bladder with a combination of adriamycin and 5-fluorouracil.

M R Robinson, P H Smith, M P Macaluso, J H Mulder, J A Martínez-Pinéiro, L Cifuentes-Delatte, A Bono, R W Glashan.   

Abstract

52 patients with advanced bladder cancer, no longer controlled by conventional therapy, have been treated by combination chemotherapy with Adriamycin and 5-fluorouracil. The objective remission rate has been 40%. The morbidity of the chemotherapy has not been excessive. The response has not been related to the histological grade of the primary tumour and previous treatment. Patients with a good performance status (Karnofsky index) have responded better than those with a poor performance status.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 913456

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  11 in total

1.  Chemotherapy of bladder tumours.

Authors:  M Pavone-Macaluso
Journal:  Urol Res       Date:  1978

2.  Three-drug combination chemotherapy for advanced urothelial tract carcinoma.

Authors:  S Ohshima; Y Ono; T Fujita; Y Aso
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 3.  Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.

Authors:  F M Torti; W G Harker
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Cooperative studies of systemic chemotherapy. A review of the work of the EORTC Urological Group and of the Yorkshire Urological Cancer Research Group (YUCRG).

Authors:  P H Smith; J A Child; J H Mulder; A T Van Oosterom; J A Martinez-Pineiro; B Richards; G Stoter; O Dalesio; M De Pauw; R Sylvester
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder.

Authors:  A Maru; H Akaza; S Isaka; K Koiso; T Kotake; T Machida; Y Matsumura; Y Nakagami; T Niijima; K Obata
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.

Authors:  K Tashiro; T Machida; F Masuda; Y Ohishi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.

Authors:  T Kotake; M Usami; T Miki; M Kuroda; K Obata; M Osafune; H Fujioka; Y Takasugi
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Combination chemotherapy for advanced urothelial-tract carcinoma.

Authors:  M Sahashi; Y Ono; O Matsuura; S Ohshima; M Fukushima
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 9.  Chemotherapy of advanced transitional-cell carcinoma of the bladder.

Authors:  R S Miller; F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Results of systemic chemotherapy of advanced bladder carcinomas (phase II study).

Authors:  G Stadie; A Möller; H Müller; D Katenkamp; H Urban; D Kob
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.